Shorter hepatitis c treatment may be just as effective
NCT ID NCT07702396
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study tests whether 12 weeks of a three-drug antiviral combination works as well as 24 weeks for curing hepatitis C in people with chronic liver disease. Researchers will enroll 192 patients who have not been treated before and randomly assign them to either the shorter or longer course. The main goal is to see if the virus stays undetectable 12 weeks after treatment ends, which would indicate a cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of sofosbuvir, daclatasvir, and ribavirin
- What this could lead to
- If 12 weeks works as well as 24, it could simplify hepatitis C treatment, reduce side effects, and lower costs for patients worldwide.
- What could go wrong
- This is a single-center study with 192 patients, so results may not apply to everyone. The shorter course might be less effective in some patients, and ribavirin can cause anemia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPTATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indus Hospital and Health Network
Karachi, 75510, Pakistan